Reviewer #1 (neuro-immune crosstalk)(Remarks to the Author):
majority of the total events (99% & 98% here) fell in the left-lower-quadrant. Plus, it would be more persuasive to show the isotype controls of these samples. Supplementary Fig. 1h : "marge" or maybe "merge"?
Reviewer #3 (glaucoma, IOP model)(Remarks to the Author):
This is a manuscript reporting data that suggest that a relatively short term IOP elevation (3 weeks) induces an acute neurodegeneration as well as chronic neurodegeneration which is mediated by T cell infiltration of the retina. The authors determined that at least some of these T cells are reactive to HSPs. Given the similarity between bacterial and human HSPs the authors then proceeded to show that in animals raised under germ-free condition the chronic neurodegeneration phase does not occur. Finally the authors report that patients with glaucoma have elevated T-cell responsiveness to HSPs compared with control groups. The experimental work performed is well described and without deficiencies in the experimental design and performance. Controls are rigorous and experiments are robust. Use of two separate glaucoma models significantly strengthens the manuscript and some of the conclusions reached. Inclusion of multiple controls also adds confidence. A few additional pieces of data and a better discussion would further strengthen this manuscript: 1. It would be useful if the authors could provide an indication of the spatial distribution of T-cells infiltrating the retina after IOP elevation. Is it diffuse or localized in clusters? Is it more prominent in one or more quadrants? Is it more common in center or periphery? 2. In Figure 3 quite a bit of immunostaining for HSP27 is seen extracellularly. Why is that? 3. Discussion is appropriate but fails to include two very relevant papers: One by Gramlich et al (Acta Neuropathol Commun. 2015 Sep 15; 3:56) , also reports involvement of T-cells in glaucoma neurodegeneration. However, contrary to what the authors report here, the previous paper documents that neurodegeneration can be caused by adoptive transfer of T-cells even in the absence of IOP elevation. The authors of the present manuscript should discuss the possible reasons for this discrepancy. The other is the paper by Astafurov et al (PLoS One. 2014 Sep 2; 9(9) :e104416) who reported that peripherally administered LPS can exacerbate neurodegeneration in glaucoma. Again the authors should discuss how their work relates to those findings. In addition discussion fails to comment on a number of unanswered questions: a. Why does neurodegeneration in the retina and ON continue after IOP normalizes? If activated Tcells can access these tissues without IOP elevation, then why don't they do so in the rest of the CNS? b. Do other conditions that involve HSP upregulation and tissue damage (which presumably would also sensitize T-cells) cause neurodegeneration in the retina and ON? c. Who are the effector cells that cause neurodegeneration? Are they T-cells? B-cells? Microglia? Monocytes? Astrocytes? Microglia numbers are provided by the authors but despite a decline in microglial activation after normalization of IOP damage continues. Why? d. Although one can envision how T-cells "see" HSPs when there is cell/tissue damage it is unclear how they would "see" HSPs in an intact RGC. Obviously many of these questions cannot be answered with the current level of knowledge but it would be important for the authors to at least speculate on possible mechanisms. Nevertheless this is a very important study and the amount of work done is exceptional.
#3, this study has been done by another group (Gramlich et al, 2015 Acta Neuropathol Commun) , using T cells isolated from at least 2 mouse lines that show an elevated IOP due to genetic mutations to wild-type recipients. Their results are in agreement with our finding presented in this paper, which support a role for T cell-mediated responses in glaucomatous neural damage. This study and its citation have now been included (Ref. #34; .
"2. Transfer of T cells specific for human MBP is not a relevant control (Figure 3 )." Response: We apologize for a potential confusion here. In our study, human MBP was used as a control antigen for culture stimulation in ELISPOT assays, in which we demonstrated that ocular hypertension induced a T cell response specific to HSPs, but not to MBP or IRBP (Fig. 3d ). We agree with the reviewer that transfer of T cells specific for human MBP is not a relevant control. Instead, we used T cells isolated from naïve or saline-injected mice with normal IOP as the controls (Fig. 2) . We have revised the text and clarified this potential confusion (lines 157 -158).
"3. The authors should test whether the effect is due to effector or regulatory T cells; transferring the total T cell population is not informative enough."
Response: To test potential effector cells, we have analyzed cytokine expression by CD4 + T cells from spleens and eye draining LNs. Our data show that elevated IOP induced CD4 + T cell expression of IFN-γ (T H 1), IL-4 (T H 2), IL-17 (T H 17) and TGF-β (Treg) without apparently biasing toward any specific subset ( Supplementary Fig. 2b ,c and lines 146 -152). These results support the induction of CD4 + T cell responses by elevated IOP. While it is more informative to transfer T cell subsets, it is technically more challenging as enough subsets of T cells have to be sorted from diseased mice without using intracellular cytokine staining. Moreover, as it has been reported in other disease models, it is very likely that not only a single subpopulation, but multiple different T cell subsets are involved in mediating the autoimmune process, as we have mentioned in the Discussion section (lines 377 -381). We are certainly interested in examining this issue in the future.
"4. In Figure 4 the authors claimed that they isolated T cells from the retina and expanded them with specific HSP27 antigen. How many T cells could be isolated? Does the expanded population also include regulatory T cells?" Response: We have now added that ~1,000 CD4 + T cells were detected per glaucomatous mouse retina by flow cytometry ( Fig. 1e ; lines 216 -217). Only INF-γ + CD4 + double-labeled T cell population was detected, indicating that they are T H 1 type cells; we were unable to detect the other subsets of CD4 + T cells (T H 17, T H 2, and Treg) in the expanded cell population, likely because they constituted a very small proportion of the infiltrating T cells. This has now been clarified (lines 217 -220).
"5. The lack of neuronal death in GF DBA1 mice cannot be interpreted to prove the role of T cells. The authors should have crossed DBA1 with Rag1-/-mice to demonstrate this effect." Response: The genetic mutation(s) in DBA/2J mice that lead to IOP elevation and the glaucoma phenotype have (has) not been identified. Transfer of Tyrp1 b and Gpnmb R150X mutations identified in DBA/2J mice to B6 mice (by crossing DBA/2J with B6 mice) induced a DBA/2J-like iris disease without the development of high IOP or glaucomatous neural damage. To carry out the study suggestioned by the reviewer, one would need to knockout Rag1 in DBA/2J mice or breed Rag1 -/onto the DBA/2J background (ideally for 20 generations). Even after doing all this and if positive results were obtained, one may still question whether this outcome proves the role of T cells or is a result of a varied genetic background.
By re-deriving germ-free DBA/2J mice, our result provides the compelling evidence that elevated IOP in glaucoma does not directly attribute to progressive neurodegeneration; it is the subsequent event known to involve the immune system and T cell responses that plays a key role in this process. Although the lack of neuronal damage in GF DBA/2J mice cannot be interpreted as a direct prove for the role of T cells by itself, our results together demonstrate a critical role for T cells in glaucomatous neurodegeneration and the important role of how microflora contributes to it. We appreciate very much the reviewer's point and have now added a paragraph in the Discussion section to clarify this notion (lines 318 -324).
Reviewer #2:
"In our opinion, the manuscripts structure should be reorganized to yield a better overview. Also, the separation of figures in main figures and suppl figures is quite misleading. Additionally, some figures do not show the indicated data, and even worse, some figures show the exact same data." Response: We have now carefully gone through the entire manuscripts and rearranged the structure as well as some of the main and supplementary figures accordingly to eliminate duplications and give a better flow of the results.
General Comments:
"Please include a detailed list of the number of animals, strain and sex as well as age. "6 to 8 mice per group" is not scientific statement. The description of animal numbers in the figure legends is misleading. Please improve the Material part by including the suppliers of chemicals and instrument and their site of location." Response: The numbers of animals of each experiment were updated, and more details on strains, sexes, and ages have now been included (lines 397 -403); suppliers of chemicals and instruments and their site of location have now been added to the Material and Methods section.
Specific Comments:
Line 111: Supp Fig 1 b does not show triple staining as indicated in the text, but cd11b staining as indicated in the figure legends. Arrows are hardly visible. Response: Supplementary Fig. 1b was misplaced to 1d. This error has now been corrected. The arrows in Supplementary Fig. 1b have been enlarged to make them more visible.
Line 114: Fig 1 c: Specify T cells as CD3-positive cells, same procedure for fig. 1 d. Response:
We have now specified that CD3 is a general T cell marker (line 93) and clarified in Fig. 1d legend (line 733) that CD4 + detects a T cell marker.
Line 115, Figure 1e : For the FACS part, why only the CD4+ cells were chosen? And how many events were recorded for each FACS sample? The method part of CD4 flow cytometry is absent. Response: The procedure of flow cytometry analysis has now been added to the Methods section, and over 20,000 events were recorded from each sample (lines 516 -527).We have also clarified that to define the subpopulations of infiltrating T cells, we performed immunolabeling and flow cytometry analysis for CD4 and CD8 T cells, and only CD4 + T cells were detected (lines 98 -102). Hence, our subsequent studies have focused on CD4 + cells.
Line 118: Supp Fig 1 d : It is impossible to distinguish red and purple signals in the merged image. Please provide the single channels and a merged image. Scale bar is missing. Response: The single channels and the merged images, with a scale bar, have now been added ( Supplementary Fig. 1b ). Response: We have now included the different concentrations of MB and described the results in further detail in both the main text (lines 105 -110) and the figure legends for Fig. 1h (lines 743 -744) and Supplementary Fig. 1c (line 869).
Line 123: Figure describes DBA mice as 8-10 months old. Text says mice were 8 months old. Please clearly indicate how many animals were included with the exact age and standard deviation. Response: We have now clarified in both Fig. c and Supplementary Fig. 1 legend that for 3 (n=6) and 8 (n=8) months old DBA/2J mice (line 732 and 871). The IOP and RGC quantification data taken from 10 month old DBA/2J mice included in the previous Supplementary Fig. 1f fig. 1 h and j) . Response: We have now clarified in both the main text (lines 117 -118) and the legend to Fig. 1h (line 750), that Tuj1 immunolabeling was used primarily to quantify RGC loss.
Line 138: The percental RGC loss/ axonal loss only presents the previous data after calculation. We recommend to exclude this data and to add IOP data on the secondary y-axis to fig 1 h/i. Response: To be consistent with the data presentation in the rest of the manuscript, we have now deleted original Fig. 1h ,i which represent the RGC and axon densities while moved the original Fig. 1j ,k that showed the percentages of RGC and axonal loss to Fig. 1h ,i. The IOP data has been added to the secondary y-axis of the current Fig. 1h ,i as it is more visible in this presentation than when we had added them to the original Fig.  1h ,i.
Line 140: I recommend to display CD3, CD4, CD11b data in a compact subfigure in the main figure 1 to yield a better overview. Response: We appreciate the reviewer's comments and have now changed the subfigure accordingly.
Line 151: How would you explain that neurodegeneration is hampered in TCRß mice in RGCs but not in axons?
Response: We have now clarified: "In TCRβ -/mice, which lack CD4 + αβT cells but are compensated by expansion of γδ and NK T cells and B cells, no significant further loss of RGCs was detected between 2 and 8 weeks after MB injection; whereas, attenuated albeit significant loss of axons was observed at 8 weeks. The data suggest a primary role for CD4 + αβT cells, with a possible involvement of other immune cells, in glaucomatous neural damage." (lines 136 -140).
Line 157: Why only CD4+ cells were transferred other than CD3+cells or just memory T cells, such as CD4+CD27+CD28+ cells, more specifically? Response: CD4 + T cells were transferred because we noted that the majority of T cells which infiltrated the glaucomatous retinas were CD4 + . We have also analyzed cytokine expression by CD4 + T cells from spleens and eye draining LNs. Our data revealed that elevated IOP induced CD4 + T cell expression of IL-17 (T H 17), IFN-γ (T H 1), IL-4 (T H 2) and TGF-β (Treg) without apparently biasing toward any specific subset ( Supplementary Fig. 2b,c; lines 146 -152) . These results support the induction of multiple subsets of CD4 + T cells by elevated IOP, and suggest that it may be most effective to transfer all, rather than a subset of CD4 + T cells. This was clarified (line 155).
To further clarify, we have also added in the Discussion section: "At this point, little is known regarding which subsets of T cells serve as effector cells or act as initiators of glaucomatous neurodegeneration. Involvement of multiple different effector T cell subsets in experimental autoimmune encephalomyelitis, via overlapping or distinct mechanisms, has been documented. Similar mechanisms can also be involved in glaucomatous neurodegeneration considering that IOP elevation induced activations of all four subsets of CD4 + T cells in the spleens and draining LN." (lines 375 -381). We are definitely interested in further examining the involvement of specific subsets of T cells in the future, including looking at memory T cells.
Line 158: It is confusing here: was the MB injection simultaneous for these two strains? Or the MB injection in the Rag1-/-was 14 days earlier than in the B6 mice? Response: We have now rewritten the sentence to clarify that Rag1 -/mice received MB injection 14 days earlier, the same day as the donor mice received MB injections (line 159).
Line 161: Fig 2 d : Please show CD4/TUJ1/DAPI images for MB, U and S group. A quantification of CD4 positive cells per group is missing. Response: Quantification of CD4 + T cells has now been added (Fig. 2f ). Anti-CD4-labeled images of S and MB-injected groups and anti-CD4/Tuj1/DAPI triple-labeled image of the MB-injected group are included ( Fig. 2d,e ).
Line 163: Why does the uninjected mice (U) show 15% loss in RGC and axons?
Response: We have now clarified in the Fig. 2d -h legend that "U" represents the group of glaucomatous (MB-injected) Rag1 -/recipient mice that received no CD4 + T cell transfer (uninjected or no T cell transfer). Moreover, we stated in the revised manuscript: "Two weeks after CD4 + T cell transfer (or 4 weeks after MB injection), glaucomatous Rag1 -/recipients that had not received any injection of CD4 + T cells (U)… as expected, exhibited ~15% RGC and axon losses as a result of the elevated IOP-induced initial phase of neural damage (Fig. 2g,h) . In contrast, MB injected glaucomatous Rag1 -/recipients that had received a CD4 + T cell transfer from glaucomatous (MB-injected) B6 mice showed retinal T cell infiltration and a significant further increase in RGC and axon loss ..." (lines 160 -167) Line 166: Supp Fig 2 b -e, indicate as percental loss to facilitate comparability to figure 2 f and g. Response:
Shown above are the bar charts converted from RGC and axon density comparisons to the percentage loss. We find these charts rather confusing as they tend to distract readers to the smaller than 2% differences between groups rather than to focus on the little differences in RGC and axon densities between mice received control or diseased T cell/IgG transfers as shown in the original figure. Therefore, we decide not to convert the charts but present the converted bar charts above for the reviewer to see our point.
Line 168: Replace "diseased" by "conditioned" Response: This has been changed.
Line 174: protein levels or antibody levels? It is not clear why they focus on protein levels in the later part when autoantibodies are differently regulated in patients and animal models. Response: We have added "proteins" following "HSP27 and HSP60" in the original line 174 (current line 181) to clarify that these were protein levels. We have further clarified that "to define the autoantigens that stimulate T cell activation in glaucoma,… which may be expressed at a low level under the normal condition but are upregulated in RGCs in glaucoma", we examined the levels of expression change of HSPs before and after IOP elevation (lines 176 -181).
Line 177: How can you prove that HSP60 was found in other layer? Retinal traverse sections would be more useful in this approach to identify colocalization in specific layers of the retina. Response: Yes, immunostaining for HSP27 and HSP60 was performed in retinal transverse sections, and these data have now been included ( Supplementary Fig. 2h ).
Line 179: Indicate that this data is about antibodies. Why did the authors exclude the 8 weeks post injection time point?
Response: It is now stated in both the text and figure legend that the data is about antibodies. The data of 8 weeks post injection was included but was mis-labeled for "4w" in the previsou Fig. 3c . This has now been corrected, and we apologize for the error.
Line 185: Fig 3 d : µm instead of mm Response: This has been corrected.
Line 187: Supp Fig 3a, Rag-/-wit saline injection is missing. Quantification of CD4-positive cells is missing. Response: As almost no T cells were detected in the retina of saline-injected Rag1 -/mice, similar to what had been shown in the retinal flat-mount image of MB-injected Rag1 -/mice in Fig. 3a , we do not feel that it is necessary to show two images with a balck background. DTH responses are commonly quantified by measuring ear thickness, as we have shown in Fig. 3c . Counting infiltrating CD4 + T cells in ear sections is merely a duplication but a less used method for DTH response quantification compared to assessing ear thickness. However, we include the images of T cell immunolabeling taken from the ear sections of WT and Rag1 -/mice as they present clearly visible differences. Supp fig 3 d and e to fig 4. Response: Supplementary Fig. 3d ,e have now been moved to Fig. 4e ,f.
Line 218: Include
Line 246: HSP27 staining quantification is missing. CTRL group images are not convincing. Response: The photomicrographs of HSP27 immunostaining in the normal IOP groups of SPF and GF mice have been replaced with better quality and more convincing images. The staining was performed for 3 mice per group, and we did not notice significant differences between the GF and SPF group before and after IOP elevation. This point has now been clarified (lines 256 -259). Figure 3 quite a bit of immunostaining for HSP27 is seen extracellularly. Why is that? Response: We have now clarified: "HSP27 upregulation was found primarily in the GCL ( Supplementary  Fig. 2h ), both associated with RGC membranes and outside RGC bodies (Fig. 3b) . This is consistent with the report that HSP27 is also upregulated in astrocytes following elevated IOP and be released extracellularly under stress 18, 19 ." (lines 183 -186).
In

Discussion is appropriate but fails to include two very relevant papers:
One by Gramlich et al (Acta Neuropathol Commun. 2015 Sep 15; 3:56) , also reports involvement of T-cells in glaucoma neurodegeneration. However, contrary to what the authors report here, the previous paper documents that neurodegeneration can be caused by adoptive transfer of T-cells even in the absence of IOP elevation. The authors of the present manuscript should discuss the possible reasons for this discrepancy. The other is the paper by Astafurov et al (PLoS One. 2014 Sep 2; 9(9) :e104416) who reported that peripherally administered LPS can exacerbate neurodegeneration in glaucoma. Again the authors should discuss how their work relates to those findings. Response: We appreciate the reviewer's comments and have now added in the Discussion section: "induction of retinal damage by adoptive transfer of CD4 + T cells is associated with local injury/inflammation… This is seemingly supported by the observation that peripheral administration of LPS exacerbated neuron loss in glaucoma 33 . Another report, however, showed that neurodegeneration could be induced in mice even with a normal IOP 8 weeks or longer after adoptive transfer of T cells isolated from genetic mouse models of glaucoma 34 . It suggests that activated T cells of glaucomatous mice are capable of entering the retina with an intact blood-retinal barrier, although probably at a much slower rate or under certain conditions." (lines 368 -376)
In addition discussion fails to comment on a number of unanswered questions: a. Why does neurodegeneration in the retina and ON continue after IOP normalizes? If activated T-cells can access these tissues without IOP elevation, then why don't they do so in the rest of the CNS? Response: We have now clarified further: "autoimmune responses in the retina start with activation of microglia, ...which leads to retinal production of inflammatory cytokines, such as TNF-α and IL-1β, that can continue after IOP returns to a normal range. These cytokines weaken the blood-retinal barrier, allowing or facilitating more T cell infiltration into the retina 37,38 ... Localized cytokine induction and microglia activation likely has limited the neural damage to the eye rather spreading widely to other sites of the CNS. " (lines 382 -392)
b. Do other conditions that involve HSP upregulation and tissue damage (which presumably would also sensitize T-cells) cause neurodegeneration in the retina and ON?
Response: We have now added: Other studies from our group have revealed that "T cell sensitization and progressive neurodegeneration were also noted in other conditions involving HSP upregulation, including retinal ischemia and optic nerve trauma (unpublished data)." (lines 363 -365)
c. Who are the effector cells that cause neurodegeneration? Are they T-cells? B-cells? Microglia?
Monocytes? Astrocytes? Microglia numbers are provided by the authors but despite a decline in microglial activation after normalization of IOP damage continues. Why? Response: We have now added: "At this point, little is known regarding which subsets of T cells serve as effector cells or act as initiators of glaucomatous neurodegeneration. Involvement of multiple different effector T cell subsets in experimental autoimmune encephalomyelitis, via overlapping or distinct mechanisms, has been documented. Similar mechanisms can also be involved in glaucomatous neurodegeneration considering that IOP elevation induced activations of all four subsets of CD4 + T cells in the spleens and draining LN." "Activated CD4 + T cells can cause neuronal damage directly as seen in multiple sclerosis or by activating other immune cell types, such as microglia, through secreted cytokines such as "d. Although one can envision how T-cells "see" HSPs when there is cell/tissue damage it is unclear how they would "see" HSPs in an intact RGC." Response: We have now further clarified in the Discussion section: "It has been reported that membranebound and extracellular HSPs, which are likely to be seen by antigen presenting cells and T cells, elicit immune responses of the adaptive or innate immune system 32 . Our results show that elevation of IOP upregulates membrane-bound and extracellular HSPs in the GCL, subsequently leading to immune-mediated neural damage through activating HSP-specific CD4 + T cells which are originally induced by microbial HSPs." (lines 354 -357) .
This reviewer remains unconvinced regarding the suggested relationships between the elevation of IOP and neuronal loss. The authors did not perform some of the critical experiments suggested, and instead cited studies by other scientists.
Additional comments: Figure 1 d: • Percentage of CD4 T cells needs to be defined relative to the parent population in the graph. • T cell subtypes in the retina need to be gated out of total leukocytes. Since different subtypes of T cells were identified in the CLN and spleen, the same subtypes must be identified in the retina to verify exactly which CD4 T cell subset is infiltrating at the different time-points tested. The detailed characterization of the infiltrating T cell subtypes will further substantiate whether this model leads to autoimmunity. • A graph showing the absence of CD8 T cells is missing. Figure 4 Adoptive transfer of HSP-specific T cells or OVA T cells and RGC/AXON count must be performed in Rag mice as well, to prove that HSP specific T cells are the ones that mediate the pathology. The manuscript raised high concerns about the roles of microbiota infection in glaucomatous pathogenesis. After revision, it has been now progressively improved, but still remains some questions unanswered.
General comments: 1. TGF-beta is not more convincing than Foxp3 as a marker for Treg. Why did the authors choose TGF-beta as the indicator of Tregs? And the discussion of the roles of those subpopulations of CD4+ cells is not sufficient.
Line 290:
The conclusion that HSP27-and HSP60-specific B cell responses are also elevated in patients with POAG and NTG, drawn from the titers of HSP27-and HSP60-specific IgGs titers changes, is not so persuasive. Direct evidence is needed. 3. Line 388: Authors mentioned and cited the weakening of blood-retinal barrier several times: did they observe direct evidences proving the blood-retinal barrier was hyperpermeable in the MB injected eyes in their study, e.g. fluorescein angiograph, subretinal leakage ... ? The citation 38 seemed to be improper here as it talked more about the retardation of blood flow in glaucoma patients, providing insufficient grounds here.
Response:
We have now clarified that the percentage of CD4+ T cells was gated out of IFN-γ+ cells in Fig. 1D . Indeed, we analyzed the CD4+ T cell subsets in the retina with flow cytometry as we did for the CLN and spleen; however, likely due to the small number of T cells that have infiltrated the retina, the only subset we were able to detect was IFN-γ+ CD4+ cells. This has now been clarified (Page 4, lines 102 -106, and Fig. 1 legend/Page 24, lines 760 -762). We are somewhat confused about what the reviewer is looking for with the request for a graph showing the absence of CD8+ T cells. The image would be very similar to the graph shown in the "Saline" group of Fig. 2D . We have now added "(data not shown)" in the text to clarify that such an image is not provided (Page 4, line 100).
" Figure 4 .Adoptive transfer of HSP-specific T cells or OVA T cells and RGC/AXON count must be performed in Rag mice as well, to prove that HSP specific T cells are the ones that mediate the pathology." Response: We performed this study, but we do not quite understand the reviewer's reasoning that performing adoptive transfer of HSP-specific T cells into Rag1 -/mice is needed to prove that the HSP-specific T cells mediate the pathology, especially given that we have already showed the data in WT mice. Our result demonstrated that adoptive transfer of T cells isolated from HSP27-immunized mice significantly exacerbated RGC and axon loss in glaucomatous B6 mice. The immune environment in Rag1 -/mice has little similarity to that of human patients with glaucoma, partly due to the mice's lack of both T and B cells and low cellularity in the thymus. Nevertheless, we have performed the experiment suggested by the reviewer, and the results show that adoptive transfer of T cells of HSP27-immunized mice, but not of OVA-immunized mice, augments RGC loss in Rag1 -/mice too. We mention this result in the Discussion section (Page 10, lines 321 -324).
" Figure 5e . The scale needs to be changed. Asterisks indicating significance are missing from the ASF graph." Response: Statistical significance asterisks have now been added to the ASF group in Fig. 5e,f. "Supplementary 4 a. The graph needs to be more clearly presented. b. Three mice per group are not sufficient for IHC." Response: We have now provided better quality graphs for Supplementary Fig. 4 . In addition, we performed IHC in 2 additional mice and found consistent upregulation of HSP-27 in the GCL of GF SW mice following IOP elevation, similar to that was seen in SPF mice. The data have now been updated ( Supplementary Fig. 4 .
Reviewer #2:
"1. TGF-beta is not more convincing than Foxp3 as a marker for Treg. Why did the authors choose TGF-beta as the indicator of Tregs? And the discussion of the roles of those subpopulations of CD4+ cells is not sufficient." Response: We appreciate the reviewer's point and understand that Foxp3, being a transcription factor, is a well-defined marker for Treg while anti-TGFβ may label additional CD4+ T cell subpopulations that exert a regulatory function, such as T H3 cells. Rather than trying to distinguish the involvement of Treg from other CD4+ T cell subpopulations (e.g. T H3 cells), we used cytokine profiles to define functional T cell subsets, which are known key contributors to immune diseases. The characterization is likely to be more inclusive than Foxp3 immunolabeling which may exclude other potential CD4+ T cell players, such as T H3 . We have now clarified this notion and further expanded on the discussion of the roles of the subpopulations of CD4+ T cells in glaucoma, as recommended by the reviewer (Page 12, lines 388 -400).
